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Abstract
Background: Approximately 100 common breast cancer susceptibility alleles have been identified in genome-wide
association studies (GWAS). The utility of these variants in breast cancer risk prediction models has not been
evaluated adequately in women of Asian ancestry.
Methods: We evaluated 88 breast cancer risk variants that were identified previously by GWAS in 11,760 cases and
11,612 controls of Asian ancestry. SNPs confirmed to be associated with breast cancer risk in Asian women were
used to construct a polygenic risk score (PRS). The relative and absolute risks of breast cancer by the PRS percentiles
were estimated based on the PRS distribution, and were used to stratify women into different levels of breast cancer
risk.
Results: We confirmed significant associations with breast cancer risk for SNPs in 44 of the 78 previously reported loci
at P < 0.05. Compared with women in the middle quintile of the PRS, women in the top 1% group had a 2.70-fold
elevated risk of breast cancer (95% CI: 2.15–3.40). The risk prediction model with the PRS had an area under the
receiver operating characteristic curve of 0.606. The lifetime risk of breast cancer for Shanghai Chinese women in the
lowest and highest 1% of the PRS was 1.35% and 10.06%, respectively.
Conclusion: Approximately one-half of GWAS-identified breast cancer risk variants can be directly replicated in East
Asian women. Collectively, common genetic variants are important predictors for breast cancer risk. Using common
genetic variants for breast cancer could help identify women at high risk of breast cancer.
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Background
Genome-wide association studies (GWAS) to date have
identified approximately 100 genetic loci associated with
breast cancer risk [1–12]. Approximately 10 of these loci
were initially identified in GWAS conducted in East
Asian descendants [7–12]. Virtually all other loci were
initially identified in studies conducted with European
descendants. In a recent study, we confirmed a signifi-
cant association in East Asian women for 31 of the 67
independent breast cancer susceptibility loci reported
from previous GWAS conducted mostly in European de-
scendants [13]. Previously we constructed an eight-SNP
polygenic risk score (PRS) and found it to be the third
strongest predictor for breast cancer risk, behind waist-
to-hip ratio and previous benign breast disease. Adding
the PRS to a predictive model including these two risk
factors increases the area under the receiver operating
characteristic curve (AUC) from 0.6178 to 0.6295 [7].
More recently, a relatively small study with 411 breast
cancer cases and 1212 controls conducted in Singapore
Chinese participants reported that a PRS constructed
from 51 SNPs improved the classification of 6.2% of the
women for their absolute risk of breast cancer in the
next 5 years [14].
We have recently identified several new genetic vari-
ants associated with breast cancer risk among women of
Asian ancestry [8–12]. As more breast cancer risk-
related genetic variants are found, it is important to in-
vestigate the public health impact of those genetic vari-
ants to identify susceptible subgroups of individuals at
elevated breast cancer risk to provide cost-efficient pre-
vention strategies and to make appropriate healthcare
decisions. In this study, we investigate the value of gen-
etic information in predicting breast cancer risk in
women of East Asian ancestry.
Methods
Study populations
This study gathered data from 11 participating case–
control studies from three sources: 12,893 women (6269
cases and 6624 controls) of East Asian origin participat-
ing in nine studies in the Breast Cancer Association
Consortium (BCAC) that were conducted in China,
Japan, South Korea, Thailand, and Malaysia; 5152
Chinese women (2867 cases and 2285 controls) from the
Shanghai Genome-Wide Association Studies (SGWAS)
who were participants in the Shanghai Breast Cancer
Study (SBCS), the Shanghai Breast Cancer Survival
Study (SBCSS), and the Shanghai Women’s Health Study
(SWHS) (the SBCS is a population-based case–control
study, and the SBCSS and SWHS are ongoing
population-based, prospective cohort studies—all partic-
ipants in these studies were recruited in Shanghai during
the same time period from 1996 to 2005 using similar
study protocols); and 5522 Chinese women (2769 cases
and 2753 controls) who were participants in Stage 2 of
the Shanghai breast cancer Genome-Wide Association
Studies (SGWAS-stage2) [11]. In total, 23,567 women of
East Asian ancestry (11,905 cases and 11,662 controls)
were included in the current analysis (Additional file 1:
Table S1). All participating studies obtained written, in-
formed consent from all subjects and approval from
their respective Institutional Review Boards. No partici-
pant received a stipend.
Genotyping methods
Samples from the nine studies in the BCAC were geno-
typed using a custom Illumina iSelect array (iCOGS)
comprising 211,155 SNPs, as part of a large collabor-
ation for replication and fine-mapping of promising as-
sociations selected from GWAS of multiple cancers.
Detailed information about the quality control (QC) has
been described previously [5, 13]. Briefly, SNPs which
had a call rate < 95%, deviated from Hardy–Weinberg
equilibrium in controls at P < 10−7, or had genotype dis-
crepancies in >2% of duplicate samples were excluded
across all Collaborative Oncological Gene–environment
Study (COGS) consortia.
The SGWAS samples were genotyped using Affymetrix
6.0, comprising 906,602 SNPs, and Affymetrix 500 K
array, comprising approximately 500,000 SNPs [7]. Genet-
ically identical and unexpected duplicate samples were ex-
cluded, as were close relatives with a pairwise proportion
of identify-by-descent estimate > 0.25. All samples with a
call rate < 95% were excluded. SNPs were excluded if the
minor allele frequency was <1% or the genotyping con-
cordance rate was <95% in the QC sample.
The SGWAS-stage2 samples were genotyped using an
exome chip comprising approximately 50,000 SNPs with
minor allele frequency over 1%, which included most of
the GWAS-identified breast cancer variants [11].
Most SNPs included in this analysis were genotyped
directly, and some SNPs were imputed using IMPUTE
and the 1000 Genomes data as a reference panel.
Statistical methods
A total of 88 SNPs at 78 breast cancer loci identified to
date were included in this analysis. First, we evaluated
associations between each SNP and breast cancer risk
using logistic regression, assuming a log-additive genetic
model with adjustment for age, population structure
(principal components), and study sites, when applicable.
We analyzed the association between each SNP and
breast cancer risk separately for each data source. The
final associations, combining the three sources, were
derived using fixed-effect meta-analysis with inverse-
variance weights. Any SNP with an association P < 0.05
(one-sided) was considered statistically significant. Tests
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for pairwise SNP by SNP interactions were also evalu-
ated using logistic regression under the log-additive gen-
etic model with the same adjustments already stated.
Second, to investigate the association between breast
cancer risk and the combined effects of all significant
SNPs, a PRS was derived for each study participant using
the formula:
PRS ¼
Xn
i¼0βiSNPi ð1Þ
where βi is the per-allele log odds ratio (OR) for breast
cancer associated with the risk allele for SNPi, which is
the number of risk alleles (0, 1, or 2) for the SNP, and n
is the total number of significant SNPs. Thus, the PRS
summarizes the combined effect of SNPs having signifi-
cant association with breast cancer risk.
Under the multiplicative polygenic model, and given
a large number of unlinked loci, each conferring a
small effect, the population distribution of the PRS is
normal (F =N(μ, σ2)), with mean value μ and variance
σ2 [15, 16]:
μ ¼ 2
X
i
piβi ð2Þ
σ2 ¼
X
i
σ2i ¼ 2
X
i
piqiβ
2
i ð3Þ
where pi is the effect allele frequency of the SNPi,
qi = 1 − pi, and βi is the log OR.
The distribution of the PRS in breast cancer cases is also
normal (G =N(μ', σ'2)), with the parameters μ' = μ + σ2 and
σ'2 = σ2 [15, 16].
Third, the discriminative accuracy of using the PRS to
predict breast cancer risk was evaluated with the AUC,
which was calculated theoretically [17, 18] given that the
PRS distributions (F, G) are known:
AUC ¼
Z 1
0
1−G rð Þð ÞdF rð Þ ð4Þ
Additionally, the AUC was also evaluated using logistic
regression models and a nonparametric approach [19].
The AUC does not measure risk concentration, which
was evaluated with the proportion of cases followed
(PCF), as the proportion of cases that would be followed
in a program that followed the proportion q of the
population at highest risk. The proportion q is the
complementary measure, the proportion needed to
follow-up (PNF) [17, 18]. Given PNF and the PRS
distributions (F, G):
PCF qð Þ ¼ Φ Φ
−1 qð Þσ þ μ −μ0
σ
 
ð5Þ
Finally, we used an approach similar to that described
previously for the Gail model [20] to estimate the abso-
lute risk of breast cancer according to percentile of the
PRS. Specifically, we predicted the probability of devel-
oping breast cancer between ages α and α + τ for a
woman who is in PRS percentile j as:
P α; τ;ORj tð Þ
  ¼
Z αþτ
α
h1 tð ÞORj tð Þ
exp −
Z τ
α
h1 uð ÞORj uð Þ þ h2 uð Þ
 
du
 
dt
ð6Þ
where subscript 1 refers to the incidence of breast
cancer and subscript 2 refers to all other causes of
death. In Eq. (6), h1(t) is the baseline hazard rate of
developing breast cancer at age t in the reference
group, h1(t) = h
*(t)(1 – PAR), where PAR is the popu-
lation attributable risk (PAR) related to the PRS and
the theoretical prediction of the ORj for individuals in
the PRS interval j between two percentiles (u, v) ver-
sus the 40th–60th percentiles:
ORj ¼
0:6−0:4ð Þ Φ Φ−1 1−uð Þ þ σ −Φ Φ−1 1−vð Þ þ σ  
v−uð Þ Φ Φ−1 0:6ð Þ þ σ −Φ Φ−1 0:4ð Þ þ σ  
ð7Þ
PAR ¼ 1−
XΦ Φ−1 1−uð Þ þ σ −Φ Φ−1 1−vð Þ þ σ 
ORj
ð8Þ
and h*(t) is the age-specific breast cancer incidence
rate in a composite population, in urban Shanghai
during 2002 and 2003 [21] or in Korean women in
the Korean risk assessment model for breast cancer
risk prediction [22]; and h2(t) is the mortality rate at
age t from all causes of death, except breast cancer,
in the population, estimated using age-specific non-
breast cancer mortality in Shanghai in 2002 and 2003
[21] or in Korean women [22].
Results
The association between the 88 selected SNPs at the 78
genetic loci and breast cancer risk in East Asian women
are presented in Additional file 2: Table S2, Additional
file 3: Table S3, and Additional file 4: Table S4. Of those
78 loci, we observed 44 independent genetic loci that
were significantly associated with breast cancer risk at
P < 0.05 (one-sided, Additional file 2: Table S2, Additional
file 3: Table S3, and Additional file 4: Table S4). We did
not observe significant heterogeneity (data not shown) of
the association across participating studies. No significant
association with breast cancer risk was observed for the
other 34 loci.
The PRS was derived based on the effect (β) and the
number of risk alleles of a SNP carried by a woman.
Some loci had multiple SNPs. In three of these loci
(near C6orf97, ZNF365, and ANKLE1 genes), the most
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significant SNPs in Asian women (rs2046210, rs10822013,
and rs2363956) were different from the most significant
SNPs in European women (rs3757318, rs10995190, and
rs8170). Only the SNP with the most significant associ-
ation with breast cancer risk in each locus was selected for
the PRS. The PRS for Asian women therefore included 44
SNPs.
Under the multiplicative polygenic model, we observed
a standard deviation (SD) of 0.38 for the PRS distribu-
tion in East Asian women (Eq. (3)). The theoretically
predicted ORs from Eq. (4) and the observed ORs from
logistic regression models for different percentiles of the
PRS were compared with women in the 40th–60th per-
centiles (Table 1). The predicted and the observed esti-
mates for ORs were similar, which provides support for
the multiplicative polygenic model. Compared with
Asian women in the middle quintile, for Asian women
in the highest 1% of the PRS the theoretically predicted
OR was 2.77 and the observed OR was 2.70 (95% CI:
2.15–3.40); for Asian women in the lowest 1% of the
PRS, the theoretically predicted OR was 0.37 and the ob-
served OR was 0.39 (95% CI: 0.27–0.57). The OR for the
increment per decile of PRS was 1.13.
As mentioned earlier, the PCF measures the propor-
tion of cases (p) which are included in the proportion q
of individuals in the population at highest risk, while
PNF assesses the proportion of the general population at
highest risk (q) that one needs to follow in order that a
proportion p of those destined to become cases will be
followed. Given the SD of 0.38 for the PRS distribution,
we estimated that approximately 2.6% of breast cancer
cases in the general population would be found among
those who were in the top 1% of PRS (PCF = 2.6%
when PNF = 1%) (Table 2 and Fig. 1). In other words,
to detect 80% of cases, 67.8% of the population needs
to be screened (PNF = 67.8% when PCF = 80%). Given
SD = 0.38, we estimated the AUC = 0.606, which is
similar to the value of 0.602 estimated from logistic
models using the data for 5152 Chinese women from
the SGWAS. Figure 1 shows the AUC, which is also
the area under a plot of PCF versus PNF as the risk
threshold varies [18]. Based on the logistic models,
the improvement in the AUC for the 44-SNP PRS to
the breast cancer prediction model was 0.0386
(Table 1). This is greater than the AUC improvement
(0.0328) for all of the traditional breast cancer risk
factors combined from the same data (results not
shown).
An estimate of 30% of the heritability of breast cancer,
the total variability of propensity for breast cancer ex-
plained by genetic factors, was reported [23, 24], which
corresponds to SD = 0.55 for the genetic variation. We
present the AUC, PCF, and PNF for SD = 0.55 in Table 2
for comparison purposes. We estimated the AUC = 0.652
when SD = 0.55.
Table 1 Theoretically predicted OR and observed OR (95% CI)
by the PRS percentiles
PRS (%) Predicted ORa Observed OR (95% CI)
0–1 0.37 0.39 (0.27–0.57)
0–10 0.52 0.55 (0.49–0.61)
10–20 0.67 0.71 (0.64–0.79)
20–30 0.77 0.74 (0.66–0.82)
30–40 0.86 0.88 (0.80–0.98)
40–60 1.00, reference 1.00, reference
60–70 1.16 1.10 (0.99–1.21)
70–80 1.29 1.24 (1.13–1.37)
80–90 1.49 1.52 (1.38–1.67)
90–100 1.97 1.93 (1.76–2.12)
99–100 2.77 2.70 (2.15–3.40)
OR per decile of PRS 1.13 (1.12–1.14)
SDa 0.38
c-statistics for PRSb 0.602
c-statistic improvementb 0.0386 (0.0259–0.0513)
aPredicted ORs were estimated based on the PRS distribution with the SD 0.38
bThe c-statistics and the improvement of c-statistics due to the PRS over the
traditional risk factors (including age at menarche, age at first live birth,
waist-to-hip ratio, breast cancer family history, and prior benign breast
disease [21]) were estimated from the Shanghai breast cancer Genome-
Wide Association Study
CI confidence interval, OR odds ratio, PRS polygenic risk score,
SD standard deviation
Table 2 Proportion of breast cancer cases followed versus the
proportion of the general population at highest risk
PNF (%) PCF (%)
PRS, SD = 0.38a PRS, SD = 0.55b
1 2.6 3.8
5 10.3 13.7
10 18.4 23.2
20 32.2 38.5
30 44.3 51.0
40 55.0 61.7
50 64.8 70.9
60 73.7 78.9
70 81.7 85.9
80 88.9 91.8
90 95.2 96.6
95 97.9 98.6
99 99.7 99.8
aObserved SD of the PRS distribution in East Asian women
bAssumed SD of the PRS distribution, which corresponds to 30% of the
heritability of breast cancer
PCF proportion of cases followed, PNF proportion needed to follow-up,
PRS polygenic risk score, SD standard deviation
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The absolute risk estimates for Shanghai Chinese and
Korean women were compared (Table 3). Using the
predicted OR estimates in Eq. (7), the estimated PAR
(Eq. (8)) for breast cancer is 6.8% for the 44-SNP PRS.
According to this PRS value, and using Eq. (6) and the
age-specific breast cancer incidence and age-specific
nonbreast cancer mortality for women in Shanghai in
2002 and 2003 [21] or in Korean women [22], the life-
time risk (age 20–80) of developing breast cancer by age
80 for the lowest 1% of the PRS was 1.35% for Chinese
women in Shanghai and 1.31% for Korean women. The
estimated risk for the highest 1% of the PRS was 10.06%
for Chinese women and 9.81% for Korean women.
For a 50-year-old woman with an average PRS value
Fig. 1 The proportion of cases followed (PCF) versus the polygenic risk score (PRS) percentile of proportion needed to follow-up (PNF). AUC area
under the receiver operating characteristic curve
Table 3 Absolute risk estimated from the predicted OR, by the PRS percentiles
Shanghai Chinese women Korean women
PRS (%) Predicted OR Lifetime risk (%)a 10-year risk (%)b Lifetime risk (%)a 10-year risk (%)b
0–1 0.37 1.35 0.38 1.31 0.39
0–10 0.52 1.89 0.53 1.85 0.55
10–20 0.67 2.44 0.69 2.38 0.70
20–30 0.77 2.80 0.79 2.73 0.81
30–40 0.86 3.13 0.88 3.05 0.90
40–60 1.00 3.64 1.03 3.55 1.05
60–70 1.16 4.22 1.19 4.12 1.22
70–80 1.29 4.69 1.32 4.58 1.35
80–90 1.49 5.42 1.53 5.28 1.56
90–100 1.97 7.16 2.02 6.98 2.07
99–100 2.77 10.06 2.84 9.81 2.90
aLifetime risk: the risk of developing breast cancer from age 20 to 80
bTen-year risk: the risk of developing breast cancer from age 50 to 60
OR odds ratio, PRS polygenic risk score
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(40th–60th percentiles), the projected 10-year absolute
risk of breast cancer is 1.03% for Chinese women and
1.05% for Korean women.
As reported previously [13], we observed significant
heterogeneity (P < 0.05) of the SNP–breast cancer asso-
ciation by breast cancer estrogen receptor (ER) status in
multiple loci (Additional file 3: Table S3 and Additional
file 4: Table S4). As a whole, for the PRS distribution
under the multiplicative polygenic model (Eq. (3)), we
observed an SD of the PRS of 0.39 for ER-positive breast
cancer and 0.38 for ER-negative breast cancer.
Finally, we evaluated the interaction between the PRS
and age and pairwise multiplicative SNP by SNP inter-
action; no significant results were observed.
Discussion
In this study, we demonstrated the value of using com-
mon breast cancer variants, summarized as a 44-SNP
PRS, to discriminate the breast cancer risk for women of
East Asian ancestry. Compared with the recent report
for women of European ancestry [15], we found that the
PRS of common genetic variants had a smaller discrim-
inative ability to identify high breast cancer risk in Asian
women. The SD of the PRS distribution was 0.45 in
European women, while the SD in this report among
East Asian women is 0.38. There were 34 breast cancer
loci identified previously in populations of European an-
cestry that were not associated with breast cancer risk in
Asian women. In addition, previous studies found that
the association of the PRS with ER-positive breast cancer
was substantially stronger than the association with ER-
negative breast cancer in women of European ancestry
[25]. Mavaddat et al. [15] observed a striking difference
in the SD of the PRS distribution by ER status (SD of
0.50 for ER-positive breast cancer and 0.38 for ER-
negative breast cancer) in women of European ancestry.
By comparison, a much less striking difference in the SD
of the PRS distribution by ER status was observed (SD
of 0.39 for ER-positive breast cancer and 0.38 for ER-
negative breast cancer) in women of Asian ancestry
(Additional file 3: Table S3 and Additional file 4:
Table S4).
We reported previously the contribution of a genetic
risk score derived from eight breast cancer-related SNPs
in the prediction of breast cancer risk [21]. The 44-SNP
PRS had greater discriminative ability than the eight-
SNP PRS reported previously [21]. The AUC improve-
ment of 0.0386 and SD = 0.38 for the 44-SNP PRS were
substantially greater than the AUC improvement of
0.0117 and SD = 0.21 for the previous eight-SNP PRS.
Previously we estimated that 37.7% of breast cancer
cases in the general population would be found among
women in the top 30% of the eight-SNP PRS values.
Based on the 44-SNP PRS, we would expect to find
44.3% of breast cancer cases among those women, a
moderate improvement for targeting women with a high
risk of breast cancer for screening. If all genetic effects,
estimated according to 30% of heritability of breast can-
cer [23, 24], were taken into account, we would find 51%
of breast cancer cases among women in the top 30% of
genetic risk (Table 2).
A limitation of this study is that this analysis included
original studies that identified several new genetic vari-
ants among women of Asian ancestry [8–12], which
raised an overfitting concern for the prediction model. If
those SNPs were excluded from the PRS, then the SD of
the PRS would be slightly decreased to 0.37 from 0.38,
and the AUC would be slightly decreased to 0.603 from
0.606. On the contrary, it can be anticipated that the dis-
criminative ability of breast cancer risk prediction based
on genetic factors will further increase as more studies
are conducted and more genetic variants, common or
rare, are identified in East Asian women. In this report,
there were several loci whose association with breast
cancer risk in Asian women were not significant but
were within the 95% CI of the association for European
populations (Additional file 2: Tables S2). If those loci
were included in the PRS, then the SD of the PRS would
be slightly increased to 0.39 from 0.38, and the AUC
would be slightly increased to 0.609 from 0.606. How-
ever, even when all genetic factors are taken into ac-
count (AUC = 0.652), the improvement in discrimination
quality would still not be sufficient to be considered
meaningful for clinical application. In order to increase
discriminatory accuracy, other strong predictors, such as
mammographic density and biopsy features, need to be
included.
Conclusions
We have shown that known common genetic variants are
important predictors for breast cancer risk, and using a
44-SNP PRS could help discriminate breast cancer risk in
women of East Asian ancestry, although the discrimin-
atory ability is not sufficient for clinical application.
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